Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
Salarius Pharmaceuticals changed its corporate name to Decoy Therapeutics and shifted its public-company identity to preclinical peptide-conjugate therapeutics. Company news centers on Decoy's machine-learning and AI-enabled platform for designing, engineering and manufacturing peptide conjugate drug candidates, with an initial pipeline focused on respiratory viruses and gastrointestinal cancers.
Recurring updates also cover shareholder votes, governance matters, capital-structure actions, Nasdaq listing compliance, and clinical or regulatory disclosures tied to its biotechnology programs.
Salarius Pharmaceuticals (Nasdaq: SLRX) has achieved a significant milestone by advancing the Ewing sarcoma arm of its Phase 1/2 Sarcoma trial to a second lead-in safety cohort. Patients in this cohort will receive a combination of seclidemstat, topotecan, and cyclophosphamide at a 900 mg BID dosage. The trial aims to assess the safety and efficacy of seclidemstat for relapsed/refractory Ewing sarcoma and FET-rearranged sarcomas. Currently, 13 clinical trial sites are actively enrolling patients, with anticipated data readouts in 2022.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Life Science Investor Forum on December 16, 2021. The presentation will cover the company's recent achievements and future milestones related to seclidemstat, a drug in clinical trials for Ewing sarcoma and hematologic cancers. The Phase 1/2 trials are assessing seclidemstat with chemotherapy agents and azacytidine. Investors can register for the event, which will be streamed live, and a recording will be available afterward on the company's website.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced participation in the Benchmark Company Discovery One-on-One Investor Conference on December 2, 2021. CEO David Arthur and the management team will engage in one-on-one meetings with registered investors to discuss the company’s business highlights, recent achievements, and upcoming clinical milestones. Salarius is focused on developing novel therapies for cancers, particularly its lead candidate, seclidemstat, which is in clinical trials for Ewing sarcoma and related cancers.
Salarius Pharmaceuticals (SLRX) reported a net loss of $3.7 million or $0.08 per share for Q3 2021, an increase from $1.7 million in the same period last year. The total working capital stood at $33.6 million, bolstered by a $2.7 million disbursement from CPRIT. The company is progressing with clinical trials for its lead drug candidate, seclidemstat, with 13 active sites now supporting enrollment. The Ewing sarcoma safety lead-in cohort is fully enrolled, and seclidemstat's development pipeline is expanding with new collaborations and clinical sites.
Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call on November 4, 2021, at 5:00 p.m. ET to discuss its corporate and financial results for Q3 2021. The call can be accessed via phone or online, with an archive available for 90 days post-event. Salarius is focused on developing treatments for cancers with high unmet medical needs, including their lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma and other cancers. The company has received multiple designations from the FDA, highlighting its commitment to advancing oncology treatments.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) presented significant preclinical findings at the 2021 AACR-NCI-EORTC Conference, focusing on its lead drug candidate, seclidemstat (SP-2577). The research highlights seclidemstat's unique action against FET-rearranged sarcomas, showcasing potent activity in preclinical models, especially in Ewing sarcoma and desmoplastic small round cell tumors. The data suggests seclidemstat's differentiated mechanism exceeds other LSD1 inhibitors, leading to a strategic amendment in its ongoing Phase 1/2 trial to include FET-rearranged sarcoma patients. Further studies aim to identify biomarkers for treatment sensitivity.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present virtually at the 2021 BioFuture Conference on October 5-6 in New York City. His presentation will cover the company's clinical achievements and future milestones for seclidemstat, an oral LSD1 inhibitor. Seclidemstat is undergoing a Phase 1/2 trial for Ewing sarcoma and another trial for hematologic cancers. Interested investors can register here. A recording will later be available on the company's website.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a significant achievement as its abstract on seclidemstat's potential in treating FET-rearranged sarcomas was accepted for presentation at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The research highlights seclidemstat’s mechanism of inhibiting the LSD1 enzyme, a promising area in cancer treatment. Salarius is currently evaluating seclidemstat in clinical trials for various cancers, including Ewing sarcoma.
Salarius Pharmaceuticals (Nasdaq: SLRX) has received a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT) to support its lead drug candidate, seclidemstat. This funding adds to the $33 million already reported on its balance sheet as of June 30, 2021, with up to $2.1 million remaining under the original CPRIT award. Seclidemstat is being studied for various cancers, including Ewing sarcoma, with clinical trials underway across five patient groups.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 10:50 a.m. ET. The event will be accessible virtually to registered attendees. Arthur will discuss Salarius’ recent achievements and highlight the clinical trial for seclidemstat, an oral LSD1 inhibitor, which is targeting Ewing sarcoma and other cancers. The company also plans virtual one-on-one meetings with investors. A recording of the presentation will be available on Salarius’ website post-event.